FOSAPREPITANT DIMEGLUMINE
Generic: FOSAPREPITANT DIMEGLUMINE
Hikma Pharmaceuticals USA Inc.Manufacturer
INTRAVENOUSRoute
FOSAPREPITANT DIMEGLUMINEActive Substance
2020-09-08Original Approval
FOSAPREPITANT DIMEGLUMINE is FDA application ANDA213106, sponsored by QILU PHARM HAINAN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2020-07-13
Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047; Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states
Class II2024-01-10
Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution anLack of Sterility Assurance: Aseptic process simulation failure.
Top Reported Reactions
1
DYSPNOEA
426 reports
2
INFUSION RELATED REACTION
360 reports
3
ALOPECIA
335 reports
4
FATIGUE
315 reports
5
PYREXIA
304 reports
6
HYPERSENSITIVITY
300 reports
7
NAUSEA
283 reports
8
ARTHRALGIA
276 reports
9
GLOSSODYNIA
271 reports
10
PRURITUS
271 reports